DK1917957T3 - Bioeroderbart øjenimplantat - Google Patents

Bioeroderbart øjenimplantat Download PDF

Info

Publication number
DK1917957T3
DK1917957T3 DK08002892.1T DK08002892T DK1917957T3 DK 1917957 T3 DK1917957 T3 DK 1917957T3 DK 08002892 T DK08002892 T DK 08002892T DK 1917957 T3 DK1917957 T3 DK 1917957T3
Authority
DK
Denmark
Prior art keywords
dexamethasone
implant
plga
implants
release
Prior art date
Application number
DK08002892.1T
Other languages
English (en)
Inventor
David Weber
David Chou
Lin Peng
Thierry Nivaggioli
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1917957T3 publication Critical patent/DK1917957T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Claims (5)

  1. Bioeroderbart øjenimplantat
    1. Bioeroderbart implantat til anvendelse ved behandling af en medicinsk tilstand i det humane øje, hvilket implantat omfatter 60 vægt-% dexamethason og 40 vægt-% PLGA, hvor PLGA er en blanding af PLGA med hydrofile endegrupper, der er udvalgt fra carboxyl, hydroxyl, polyethylenglycol, eller en kombination deraf, og PLGA med hydrofobe endegrupper, der er udvalgt fra en alkylester eller aromatisk ester, hvor implantatet dannes ved hjælp afen ekstruderingsproces, hvor den medicinske øjentilstand er udvalgt fra gruppen bestående af uveitis, makulært ødem, makulær degeneration, nethindeløsning, øjentumorer, svampeinfektioner, virusinfektioner, multifokal choroiditis, diabetisk retinopati, proliferativ vitreoretinopati (PVR), sympatetisk oftalmi, Vogt Koyanagi-Harada-(VKH) syndrom, histoplasmose, uveal diffusion og vaskulær okklusion.
  2. 2. Bioeroderbart implantat til anvendelse ifølge krav 1, hvor det bioeroderbare implantat er dimensioneret til implantation i glaslegemekaviteten.
  3. 3. Bioeroderbart implantat til anvendelse ifølge et hvilket som helst af kravene 1 og 2, hvor vægtforholdet mellem PLGA med hydrofile endegrupper og PLGA med hydrofobe endegrupper er 3:1.
  4. 4. Bioeroderbart implantat til anvendelse ifølge krav 3, hvor implantatet har en totalvægt på 1200 pg.
  5. 5. Bioeroderbart implantat til anvendelse ifølge et hvilket som helst af kravene 1-4, hvor implantatet er fremstillet ved hjælp af en ekstruderingsproces ved anvendelse af dobbeltsnekkeekstruder.
DK08002892.1T 2003-01-09 2004-01-07 Bioeroderbart øjenimplantat DK1917957T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/340,237 US20040137059A1 (en) 2003-01-09 2003-01-09 Biodegradable ocular implant
EP04700611A EP1581193B1 (en) 2003-01-09 2004-01-07 Biodegradable ocular implant

Publications (1)

Publication Number Publication Date
DK1917957T3 true DK1917957T3 (da) 2017-02-13

Family

ID=32711277

Family Applications (5)

Application Number Title Priority Date Filing Date
DK17188114.7T DK3305284T3 (da) 2003-01-09 2004-01-07 Bionedbrydelig øjeimplantat
DK08002892.1T DK1917957T3 (da) 2003-01-09 2004-01-07 Bioeroderbart øjenimplantat
DK04700611.9T DK1581193T3 (da) 2003-01-09 2004-01-07 Biologisk nedbrydeligt øjenimplantat
DK16198417.4T DK3187177T3 (da) 2003-01-09 2004-01-07 Bionedbrydeligt øjenimplantat
DK14165593.6T DK2799064T3 (da) 2003-01-09 2004-01-07 Bioeroderbart øjenimplantat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17188114.7T DK3305284T3 (da) 2003-01-09 2004-01-07 Bionedbrydelig øjeimplantat

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK04700611.9T DK1581193T3 (da) 2003-01-09 2004-01-07 Biologisk nedbrydeligt øjenimplantat
DK16198417.4T DK3187177T3 (da) 2003-01-09 2004-01-07 Bionedbrydeligt øjenimplantat
DK14165593.6T DK2799064T3 (da) 2003-01-09 2004-01-07 Bioeroderbart øjenimplantat

Country Status (21)

Country Link
US (1) US20040137059A1 (da)
EP (6) EP1917957B1 (da)
JP (1) JP4223040B2 (da)
KR (1) KR20050099008A (da)
CN (2) CN100364514C (da)
AT (1) ATE555779T1 (da)
AU (1) AU2004204744B2 (da)
BR (2) BRPI0406692A (da)
CA (1) CA2512315C (da)
CY (4) CY1118431T1 (da)
DK (5) DK3305284T3 (da)
ES (5) ES2384875T3 (da)
FR (1) FR12C0067I1 (da)
HK (1) HK1084021A1 (da)
HU (4) HUE044965T2 (da)
MX (1) MXPA05007342A (da)
NZ (1) NZ540451A (da)
PT (4) PT2799064T (da)
SI (3) SI3305284T1 (da)
TR (2) TR201908857T4 (da)
WO (1) WO2004062649A2 (da)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
ATE476960T1 (de) 2003-05-02 2010-08-15 Surmodics Inc System zur kontrollierten freisetzung eines bioaktiven wirkstoffs im hinteren bereich des auges
US7060723B2 (en) 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US7125908B2 (en) * 2003-08-29 2006-10-24 Allergan, Inc. Treating pain using selective antagonists of persistent sodium current
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
CA2553381C (en) 2004-01-20 2011-03-22 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
AU2005314426A1 (en) * 2004-12-10 2006-06-15 Talima Therapeutics, Inc. Compositions and methods for treating conditions of the nail unit
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
AU2011236024B2 (en) * 2005-03-01 2013-05-23 Allergan, Inc. Microimplants for ocular administration
US20060204548A1 (en) * 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
EP1917971A1 (en) 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8536190B2 (en) * 2007-01-30 2013-09-17 Allergan, Inc. Treating unwanted ocular conditions using an ascomycin macrolactam
CN101678038A (zh) * 2007-03-14 2010-03-24 华盛顿大学 用于眼内药物递送的装置和方法
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
MX2010002616A (es) * 2007-09-07 2010-08-04 Qlt Plug Delivery Inc Nucleos de farmaco para la liberacion sostenida de agentes terapeuticos.
US8353862B2 (en) 2007-11-02 2013-01-15 Allergan, Inc. Drug delivery systems and methods
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
CN102026599A (zh) 2008-05-12 2011-04-20 犹他大学研究基金会 眼内药物递送装置及相关方法
US10588855B2 (en) 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
WO2009143288A1 (en) * 2008-05-20 2009-11-26 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20110206773A1 (en) * 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
CN101612111B (zh) * 2008-06-24 2011-11-23 上海医药工业研究院 醋酸诺美孕酮或其类似物的缓释微球及其制备方法和用途
US10842669B2 (en) 2008-11-13 2020-11-24 Gholam A. Peyman Ophthalmic drug delivery method
US10272035B2 (en) 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
US20100204325A1 (en) * 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US20100303757A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303794A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
WO2011020052A1 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using opioid retargeted endpeptidases
CA2771297A1 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using neurotrophin retargeted endopeptidases
WO2011020056A2 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using galanin retargeted endpeptidases
KR20140015129A (ko) 2009-08-14 2014-02-06 알러간, 인코포레이티드 성장 인자 재표적화된 엔도펩티다아제를 사용하여 암을 치료하는 방법
CN102574899A (zh) 2009-08-14 2012-07-11 阿勒根公司 使用胰高血糖素样激素再靶向内肽酶治疗癌症的方法
WO2011020114A2 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using tachykinin retargeted endopeptidases
EP2534137B1 (en) 2010-02-08 2015-09-16 Allergan, Inc. Pyridazine derivatives useful as cannabinoid-2 agonists
US20130030055A1 (en) 2010-03-24 2013-01-31 Allergan, Inc. Compositions and methods for treating hair loss, hair thinning, and hair color loss
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
WO2012112432A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Methods of inhibiting aberrant blood vessel formation using opioid retargeted endopeptidases
US20120207742A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Treatments Using PSMA Ligand Endopeptidases
WO2012112426A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Arginine vasopressin retargeted clostridial endopeptidases for use in treating benign prostatic hyperplasia
WO2012112434A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
WO2012112422A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using growth factor retargeted endopeptidases
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EP2855030B1 (en) 2012-06-01 2019-08-21 SurModics, Inc. Apparatus and method for coating balloon catheters
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
WO2014066644A1 (en) 2012-10-26 2014-05-01 Allergan, Inc. Ketorolac-containing sustained release drug delivery systems
CA2897197C (en) 2013-01-15 2022-06-07 The Regents Of The University Of Colorado, A Body Corporate Lacrimal system drug delivery device
JP2016514024A (ja) 2013-03-14 2016-05-19 ハラックス，インコーポレイテッド 爪部の感染症、疾患または障害の治療方法
KR102307281B1 (ko) * 2013-10-31 2021-09-29 알레간 인코포레이티드 프로스타마이드-함유 안구내 삽입물 및 그것의 사용 방법
CA2939651A1 (en) * 2014-02-26 2015-09-03 Allergan, Inc. Intraocular implant delivery apparatus and methods of use thereof
JP6655610B2 (ja) 2014-05-29 2020-02-26 グローコス コーポレーション 制御された薬物送達機能を備えるインプラント及びそれを使用する方法
US10363163B2 (en) 2014-09-11 2019-07-30 EyePoint Pharmaceuticals, Inc. Injector apparatus
FR3028410A1 (fr) 2014-11-18 2016-05-20 Pierre Coulon Implant capsulaire multifonctionnel
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
USD851755S1 (en) 2015-10-22 2019-06-18 Eyepoint Pharmaceuticals Us, Inc. Ocular inserter
WO2017091404A1 (en) 2015-11-23 2017-06-01 The Regents Of The University Of Colorado, A Body Corporate Lacrimal system for drug delivery
JP7003110B2 (ja) 2016-04-20 2022-01-20 ドーズ メディカル コーポレーション 生体吸収性眼球薬物送達デバイス
JP7054211B2 (ja) 2016-05-20 2022-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 涙腺ドラッグ送給デバイス
WO2020112816A1 (en) 2018-11-29 2020-06-04 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322323A (en) * 1980-12-01 1982-03-30 Alza Corporation Erodible device comprising surfactant for modifying the rate of erosion of the device
DE3168032D1 (en) * 1980-11-10 1985-02-14 Alza Corp Erodible polymer containing erosion rate modifier
US4883457A (en) * 1983-08-18 1989-11-28 Drug Delivery Systems Inc. Disposable and/or replenishable transdermal drug applicators and methods of manufacturing same
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
JPS63291419A (ja) * 1987-05-24 1988-11-29 Tatsumo Kk 加熱処理装置
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
PT654256E (pt) * 1993-02-26 2000-12-29 Santen Pharmaceutical Co Ltd Rolha de esclerotica biodegradavel
US5707643A (en) * 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
WO1997026869A1 (en) * 1996-01-24 1997-07-31 United States Government Represented By The Secretary Of The Army Novel 'burst-free' sustained release poly-(lactide/glycolide) microspheres
EP0992244A4 (en) * 1997-07-02 2001-01-17 Santen Pharmaceutical Co Ltd SCLERAL PLUGS OF POLYLACTIC ACID
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU3649502A (en) * 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor

Also Published As

Publication number Publication date
EP1581193B1 (en) 2012-05-02
PT3305284T (pt) 2019-08-30
EP3305284A1 (en) 2018-04-11
CY1118431T1 (el) 2017-06-28
AU2004204744B2 (en) 2008-03-13
ES2613028T3 (es) 2017-05-22
BRPI0406692A (pt) 2005-12-20
EP3563839A1 (en) 2019-11-06
MXPA05007342A (es) 2005-09-30
ES2742152T3 (es) 2020-02-13
EP2799064A1 (en) 2014-11-05
NZ540451A (en) 2008-02-29
EP2799064B1 (en) 2017-11-29
CY1120147T1 (el) 2018-12-12
HUE030319T2 (en) 2017-05-29
ES2384875T3 (es) 2012-07-13
FR12C0067I1 (fr) 2012-12-14
HK1084021A1 (en) 2006-07-21
ES2735132T3 (es) 2019-12-16
SI2799064T1 (en) 2018-04-30
WO2004062649A2 (en) 2004-07-29
EP3305284B1 (en) 2019-05-15
SI3187177T1 (sl) 2019-09-30
DK1581193T3 (da) 2012-06-25
EP1917957B1 (en) 2016-11-16
EP1581193A2 (en) 2005-10-05
TR201908857T4 (tr) 2019-07-22
JP4223040B2 (ja) 2009-02-12
KR20050099008A (ko) 2005-10-12
SI3305284T1 (sl) 2019-11-29
PT1917957T (pt) 2017-01-23
WO2004062649A3 (en) 2004-11-04
DK2799064T3 (da) 2018-03-12
CA2512315C (en) 2008-12-30
CN100364514C (zh) 2008-01-30
EP3187177A1 (en) 2017-07-05
ES2661383T3 (es) 2018-03-28
EP1917957A3 (en) 2011-06-15
CA2512315A1 (en) 2004-07-29
BR122015016901B8 (pt) 2021-07-27
DK3187177T3 (da) 2019-06-24
EP3187177B1 (en) 2019-03-20
CN101259280A (zh) 2008-09-10
AU2004204744A1 (en) 2004-07-29
US20040137059A1 (en) 2004-07-15
JP2006525953A (ja) 2006-11-16
TR201802793T4 (tr) 2018-03-21
CY1121731T1 (el) 2020-07-31
CY1121912T1 (el) 2020-10-14
EP1917957A2 (en) 2008-05-07
PT2799064T (pt) 2018-03-06
CN1735405A (zh) 2006-02-15
BR122015016901B1 (pt) 2018-06-05
HUE044694T2 (hu) 2019-11-28
DK3305284T3 (da) 2019-08-19
HUE044965T2 (hu) 2019-11-28
PT3187177T (pt) 2019-06-27
HUE036209T2 (hu) 2018-06-28
ATE555779T1 (de) 2012-05-15

Similar Documents

Publication Publication Date Title
DK1917957T3 (da) Bioeroderbart øjenimplantat
US20210113592A1 (en) Ocular implant made by a double extrusion proces
AU2018236685B2 (en) Ocular implant made by a double extrusion process
AU2014201844B2 (en) Ocular implant made by a double extrusion process